Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer shortlists private equity firms to bid for pest control unit -Handelsblatt

11/19/2021 | 01:30pm EST
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

FRANKFURT (Reuters) - Bayer has shortlisted a number of private equity groups to make binding bids for its pest control unit Bayer Environmental Science (BES), Handelsblatt reported on Friday.

Cinven, CVC and Apax are among the bidders that Bayer, which earlier this year put the business up for sale, has picked for the next bidding round, the newspaper cited financial sources as saying.

Bayer, which declined to comment, is selling the unit to cut debt and to focus its crop science division on its core agriculture customers. Environmental Science offers pesticides and rodent control to non-farming customers like greenskeepers and warehouse managers.

(Reporting by Ludwig Burger; Editing by Chris Reese)


ę Reuters 2021
All news about BAYER AG
12/07German Pharma Giant Bayer Mulls Establishing Production Facility in Singapore
MT
12/06Recursion Pharmaceuticals to Expand Fibrosis Collaboration With Bayer to Include Infere..
MT
12/05Beijing biotech firm banks on GM corn in race to be China's Monsanto
RE
12/03BAYER AG : Buy rating from UBS
MD
12/03Bayer's Nubeqa Notches Clinical Trial Win in New Prostate Cancer Indication
MT
12/03Bayer's Nubeqa drug improves survival in prostate cancer trial
RE
12/03Bayer Prostate Cancer Combo Found to Extend Lives in Late-Stage Study
MT
12/03BAYER : Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel an..
PU
12/01Bayer To Make $113 Million Investment To Drive Sustainable Use Of Products
MT
12/01Bayer Invests ?100 Million in Sustainable Health Products to Advance Company's 2030 Sus..
CI
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2021 42 989 M 48 534 M 48 534 M
Net income 2021 412 M 466 M 466 M
Net Debt 2021 38 333 M 43 278 M 43 278 M
P/E ratio 2021 72,7x
Yield 2021 4,48%
Capitalization 44 907 M 50 480 M 50 700 M
EV / Sales 2021 1,94x
EV / Sales 2022 1,83x
Nbr of Employees 99 814
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 45,71 €
Average target price 62,21 €
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG-5.08%49 398
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321